Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
381-400 of 1,307 trials

Allergy Relief: Sublingual Immunotherapy for House Dust Mite Allergies

We are studying a new treatment for individuals aged 12-65 with rhinitis or asthma caused by house dust mites. The goal is to see if this therapy can improve allergy symptoms compared to a placebo.

Allergic Rhinitis and Asthma1-2 yearsConfirmation phase (III)Investigational MedicinesAllergologyPulmonology

Osteoporosis Treatment: The OPTIMIST Study on Romosozumab

We are exploring the best ways to use romosozumab for osteoporosis treatment. Additionally, we’re investigating if it has any impact on insulin sensitivity.

Osteoporosis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Postoperative Recovery: Spinal Morphine vs. Intravenous Lidocaine

We are studying if adding spinal morphine to pain management helps patients recover better after robotic-assisted upper urinary tract surgery. The goal is to see if it reduces pain and speeds up recovery compared to standard treatment.

Kidney and Ureter Disorders6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineNephrologyOncologyOtolaryngologyUrology

TAK-881 for Primary Immunodeficiency Diseases

We are studying the long-term safety and tolerability of TAK-881 in individuals with Primary Immunodeficiency Diseases. This trial will also assess how well the treatment works and its effects on patients' quality of life.

Primary Immunodeficiency Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyInfectious Diseases

Persistent Atrial Fibrillation: Cryoballoon vs. Medication

We are studying whether early treatment with a cryoballoon is more effective than antiarrhythmic drugs for people with persistent atrial fibrillation. The trial also looks at how these treatments affect quality of life and healthcare needs.

Persistent Symptomatic Atrial Fibrillation>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Basal Cell Carcinoma: Tirbanibulin (Klisyri®) Treatment Study

We are studying the effectiveness and safety of Tirbanibulin (Klisyri®) for treating superficial basal cell carcinoma. The trial will also look at how well patients tolerate the treatment and their overall satisfaction.

Superficial Basal Cell Carcinoma≤3 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatology

Anal Cancer Treatment: Induction Chemotherapy Study

We are studying a new treatment approach for locally advanced anal squamous cell carcinoma to see if adding induction chemotherapy improves outcomes compared to standard treatment. This trial will help us understand its effects on survival and quality of life.

Locally Advanced Anal Squamous Cell CarcinomaConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Systemic Sclerosis: Anifrolumab Treatment Study

We are investigating whether Anifrolumab can improve symptoms and lung function in adults with systemic sclerosis. This study compares the new treatment to a placebo to see how well it works.

Systemic SclerosisImmune System DiseasesInterstitial Lung Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Juvenile Psoriatic Arthritis: Risankizumab Study

We are studying a new treatment called risankizumab for children aged 5 to 17 with active juvenile psoriatic arthritis. The goal is to see if it is safe and effective compared to an existing medication.

Juvenile Psoriatic Arthritis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyPediatricsRheumatology

DIPG Treatment Study: ONC201 vs. Everolimus

We are testing a new drug, ONC201, for children with newly diagnosed DIPG and related tumors. The goal is to see if it helps improve survival and progression-free time compared to standard treatment.

Brain Stem Glioma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Pain Management: Dexmedetomidine for Nerve Block

We are exploring the best dose of dexmedetomidine to enhance pain relief during a nerve block procedure. This study will also check for side effects and benefits like reduced opioid use and better patient satisfaction.

Patients Scheduled for Shoulder Operations1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOrthopedics and TraumatologyOtolaryngology

EPO-TRAUMA: Epoetin Alfa for Critically Ill Trauma Patients

We are studying whether epoetin alfa can lower the risk of death and severe disability in critically ill patients after trauma. This trial compares its effects to a placebo treatment.

Traumatic Injury3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Weight Management in Schizophrenia: Semaglutide Study

We are investigating whether semaglutide can help patients with schizophrenia and obesity improve their weight and metabolic health. This study compares semaglutide to a placebo to see its effects on various health measures.

Metabolic Control in Antipsychotic-Using Patients6-12 monthsConfirmation phase (III)>20 visitsInvestigational MedicinesEndocrinologyPsychiatry

Colorectal Cancer: Reduced Dose Chemotherapy for Older Patients

We are studying whether a lower dose of chemotherapy is as effective as the standard dose for older patients with advanced colorectal cancer. This may help improve quality of life and reduce severe side effects.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Achondroplasia: Infigratinib for Children

We are investigating a new medication, infigratinib, for children aged 3 to under 18 with achondroplasia. The study aims to see if it helps improve growth and body proportions while ensuring safety.

Achondroplasia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOrthopedics and TraumatologyPediatrics

Juvenile Idiopathic Arthritis: Baricitinib Study

We are investigating whether the medication baricitinib is safe and effective for children and teens aged 1 to 17 with juvenile idiopathic arthritis. This study aims to improve treatment options for this condition.

Juvenile Idiopathic Arthritis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Efgartigimod PH20 SC for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will help us understand the right dose and evaluate its safety and effects on daily life.

Myasthenia Gravis3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Chronic Spontaneous Urticaria: Omalizumab Treatment Intervals

We are studying whether adults with well-controlled chronic spontaneous urticaria can safely extend the time between omalizumab treatments while maintaining symptom control.

Chronic Spontaneous Urticaria6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Colorectal Liver Metastases: HAIP-SYST Treatment Study

We are investigating a new combination of local and systemic chemotherapy for patients with initially unresectable colorectal liver metastases. The study aims to see if this approach improves survival and quality of life compared to standard treatment.

Colorectal Liver Metastases1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHepatologyOncology

Carbetocin Nasal Spray for Hunger in Prader-Willi Syndrome

We are studying the safety of carbetocin nasal spray for people with Prader-Willi Syndrome who experience uncontrollable hunger. The trial also looks at how this treatment may help with anxiety and caregiver challenges.

Hyperphagia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyPediatrics